A widely read initial report from the Associated Press on Monday January 3, 2011 mischaracterized the new arrangement between Veridex and Mass General around the development of a third generation system for capturing and analyzing circulating tumor cells. (Here’s one link to that report, since amended by AP.)
The news service originally presented the deal as being around an existing second-generation “herringbone” pattern CTC chip technology, originally described in a Proceedings of the National Academy of Sciences paper in October 2010. AP even ran a photo of that chip lifted from the paper.
In the meantime, MGH is continuing development of the herringbone chip, through NIH grants and other sponsorship including support from Stand Up 2 Cancer, a research funding group organized by Hollywood celebrities. Toner and Dan Haber of MGH lead one of SU2C’s five scientific “Dream Teams.”